Navigation Links
Relief From Asthma With New Combo Therapy

An inhaled corticosteroid (budesonide) coupled with a long-acting beta2-agonist (formoterol) can actually provide significant improvement of // asthma symptoms with less reliance on high doses of inhaled steroid, say researchers according to a new study.

For the study the effects of various combinations of medicine on asthma symptoms in 2,760 asthma patients at 246 centers in 22 countries were analyzed. The patients were divided into three treatment groups: a bud/form combination twice a day and as needed for relief, bud/form twice a day plus terbutaline (a short-acting beta2-agonist) as needed, and budesonide twice a day plus terbutaline as needed.

Results showed a 45-percent reduction in the exacerbation rate of asthma symptoms, a reduction in overall severe exacerbation levels, improved symptom control and lung function, and less sleep interruption in those who took the bud/form combo compared with the other two drug combinations. It was also observed that the bud/form combination helped maintain a reduction in asthma attacks severe enough to require medical attention, using a corticosteroid dose that was one-fourth the amount in the budesonide/terbutaline combo. Another positive finding from the study was that there was no evidence of a tolerance developing to the bud/form treatments, with patients maintaining their results for one year.

Page: 1

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Relief from common back pain
3. Relief to pregnant women using fertility drugs
4. Relief of pain for suffering patients
5. Relief from cancer pain with anticonvulsants
6. Relief from Migraine
7. Pain Relief For Osteoarthritis Patients
8. Relief From Migraines
9. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
10. Drug Found To Bring Relief For Individuals With Early Parkinson’
11. Relief For Women Suffering From Fibromyalgia
Post Your Comments:

(Date:11/30/2015)... ... 30, 2015 , ... Holcomb – Kreithen Plastic Surgery ... practices in Florida, is proud to announce that Dr. Joshua Kreithen, one of ... Inc., a Johnson & Johnson Company. , Ethicon is a global medical device ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” ... three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... , ... The successful filing of an Investigational New Drug application (IND) is ... this key industry segment, Regis Technologies has decided to sponsor and participate in an ... EST. , Federal law does not allow new drugs to cross state lines until ...
(Date:11/30/2015)... ... 2015 , ... Vasont Systems, a top component content management ... unites with Syncro Soft’s latest software update, oXygen XML editor Version 17.1. Users ... latest release of oXygen® XML editor and the Vasont® CCMS. , The ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... Nov. 30, 2015  Precision Image Analysis Inc. ... pleased to announce a dramatic expansion of its ... Building on its ISO-9001:2008 certification for its Quality ... Core Lab protocols and procedures. This expansion enables ... activities.  Their Core Lab services include design and ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
Breaking Medicine Technology: